Coherus Oncology (CHRS) Interest Coverage Ratio: History & Chart

Coherus Oncology, Inc.(CHRS)

Biotechnology · Redwood City, CA

$1.12-0.04 (-3.45%)

Delayed quote: Oct 5, 2026, 4:00 PM EDT

About Coherus Oncology, Inc.

Coherus Oncology, Inc. is a biopharmaceutical company primarily focused on the research, development, and commercialization of cancer immunotherapies across the United States. The company's commercialized products include several biosimilar therapies. These comprise UDENYCA, a long-acting granulocyte-colony stimulating factor biosimilar to Neulasta; YUSIMRY, an equivalent to Humira, prescribed for inflammatory conditions like rheumatoid arthritis, psoriasis, and Crohn's disease, which are characterized by heightened tumor necrosis factor (TNF) production; and CIMERLI, a Lucentis biosimilar aimed at treating specific ophthalmic disorders such as neovascular age-related macular degeneration, macular edema, and diabetic retinopathy. Beyond its commercial products, Coherus maintains a robust pipeline of investigational immunotherapies. This includes LOQTORZI, a novel, next-generation programmed death receptor-1 (PD-1) inhibitor; Casdozokitug, a recombinant human immunoglobulin G1 (IgG1) monoclonal antibody designed to target interleukin 27; CHS-114, a highly specific human afucosylated IgG1 monoclonal antibody targeting a chemokine receptor prevalent on Treg cells in the tumor microenvironment (TME); CHS-1000, an anti-ILT4 monoclonal antibody aimed at solid tumors; and GSK4381562, an antibody engineered to target CD112R on tumor cells. To support its endeavors, the company has forged several strategic alliances. These encompass a co-development and commercialization pact with Junshi Biosciences for toripalimab, as well as agreements with Surface and Adimab LLC. Its licensing portfolio includes arrangements with Bioeq AG, Genentech, Inc., Surface, and Vaccinex, Inc. Furthermore, Coherus has out-licensing agreements with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. Founded in 2010, the company currently operates as Coherus BioSciences, Inc., but is slated to officially rebrand as Coherus Oncology, Inc. in May 2025. Its headquarters are located in Redwood City, California.

Redwood City, CA

144 employees

www.coherus.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Dennis Lanfear

View full financials

CHRS Interest Coverage Ratio Metrics

INTEREST COVERAGE RATIO

-19.95x

INTEREST COVERAGE RATIO AVG TTM

-17.80x

INTEREST COVERAGE RATIO AVG 3Y

-10.94x

INTEREST COVERAGE RATIO AVG 5Y

-9.42x

INTEREST COVERAGE RATIO AVG 10Y

-10.32x

INTEREST COVERAGE RATIO AVG 15Y

N/A

INTEREST COVERAGE RATIO AVG 20Y

N/A

CURRENT VS TTM AVG

-12.08%

CURRENT VS 3Y AVG

-82.33%

CURRENT VS 5Y AVG

-111.80%

CURRENT VS 10Y AVG

-93.37%

CURRENT VS 15Y AVG

N/A

CURRENT VS 20Y AVG

N/A

SECTOR MEDIAN · HEALTHCARE

-3.33x

median of 306 covered companies

CURRENT VS SECTOR MEDIAN

-500.00%

vs the sector median at left

NAME	MARKET CAP	INTEREST COVERAGE RATIO	TTM	3Y	5Y
Coherus Oncology, Inc. (CHRS)	$173.04M	-19.95x	-17.80x	-10.94x	-9.42x
Compass Therapeutics, Inc. (CMPX)vs ›	$172.99M	N/A	N/A	N/A	N/A
Precision BioSciences, Inc. (DTIL)vs ›	$174.17M	-36.67x	N/A	N/A	N/A
Cue Biopharma, Inc. (CUE)vs ›	$176.96M	-74.29x	N/A	N/A	N/A
Canton Strategic Holdings Inc (CNTN)vs ›	$179.70M	-709.33x	N/A	N/A	N/A
ALX Oncology Holdings Inc. (ALXO)vs ›	$162.82M	-64.93x	N/A	N/A	N/A
Journey Medical Corporation (DERM)vs ›	$184.12M	-2.21x	15.94x	15.94x	15.94x
Inogen, Inc. (INGN)vs ›	$160.82M	N/A	2247.41x	1131.54x	905.57x
Acumen Pharmaceuticals, Inc. (ABOS)vs ›	$153.84M	-29.32x	N/A	N/A	N/A
Eledon Pharmaceuticals, Inc. (ELDN)vs ›	$192.97M	N/A	N/A	N/A	N/A

NAME

MARKET CAP

INTEREST COVERAGE RATIO

TTM

Coherus Oncology, Inc. (CHRS)

$173.04M

-19.95x

-17.80x

-10.94x

-9.42x

Compass Therapeutics, Inc. (CMPX)vs ›

$172.99M

N/A

Precision BioSciences, Inc. (DTIL)vs ›

$174.17M

-36.67x

N/A

Cue Biopharma, Inc. (CUE)vs ›

$176.96M

-74.29x

N/A

Canton Strategic Holdings Inc (CNTN)vs ›

$179.70M

-709.33x

N/A

ALX Oncology Holdings Inc. (ALXO)vs ›

$162.82M

-64.93x

N/A

Journey Medical Corporation (DERM)vs ›

$184.12M

-2.21x

15.94x

Inogen, Inc. (INGN)vs ›

$160.82M

N/A

2247.41x

1131.54x

905.57x

Acumen Pharmaceuticals, Inc. (ABOS)vs ›

$153.84M

-29.32x

N/A

Eledon Pharmaceuticals, Inc. (ELDN)vs ›

$192.97M

N/A

Interest Coverage Ratio FAQ

What is the interest coverage ratio for Coherus Oncology, Inc. (CHRS)?

The interest coverage ratio for CHRS stock is -19.95x.

Is Coherus Oncology, Inc.'s interest coverage ratio high or low?

The interest coverage ratio of -19.95x is 112% below its 5-year average of -9.42x, near the low end of its 5-year range (-21.13x–-1.19x).

What is the TTM average interest coverage ratio for Coherus Oncology, Inc. (CHRS)?

The TTM average interest coverage ratio for CHRS stock is -17.80x.

What is the 3Y average interest coverage ratio for Coherus Oncology, Inc. (CHRS)?

The 3Y average interest coverage ratio for CHRS stock is -10.94x.

What is the 5Y average interest coverage ratio for Coherus Oncology, Inc. (CHRS)?

The 5Y average interest coverage ratio for CHRS stock is -9.42x.

What is the 10Y average interest coverage ratio for Coherus Oncology, Inc. (CHRS)?

The 10Y average interest coverage ratio for CHRS stock is -10.32x.

DATE	INTEREST COVERAGE RATIO
2026-06-30	-13.92x
2026-03-31	-16.54x
2025-12-31	-20.40x
2025-09-30	-18.16x
2025-06-30	-19.98x
2025-03-31	-21.13x
2024-12-31	-7.90x
2024-09-30	-1.19x
2024-06-30	-3.84x
2024-03-31	-6.10x
2023-12-31	-6.49x
2023-09-30	-3.12x
2023-06-30	-3.47x
2023-03-31	-6.98x
2022-12-31	-5.49x
2022-09-30	-10.67x
2022-06-30	-6.69x
2022-03-31	-9.02x
2021-12-31	-6.83x
2021-09-30	-5.68x
2021-06-30	-4.20x
2021-03-31	-29.63x
2020-12-31	2.90x
2020-09-30	5.96x
2020-06-30	12.08x
2020-03-31	9.22x
2019-12-31	10.05x
2019-09-30	11.60x
2019-06-30	6.20x
2019-03-31	-3.94x
2018-12-31	-24.86x
2018-09-30	-23.49x
2018-06-30	-18.58x
2018-03-31	-17.46x
2017-12-31	-19.36x
2017-09-30	-23.67x
2017-06-30	-23.76x
2017-03-31	-30.48x
2016-12-31	-31.01x
2016-09-30	34.97x
2016-06-30	-26.65x
2016-03-31	-76.88x
2015-09-30	-2158.09x
2014-09-30	-6423.00x
2014-06-30	-15.49x
2014-03-31	-5.02x
2013-12-31	-3.18x
2013-09-30	-3.41x

DATE

INTEREST COVERAGE RATIO

2026-06-30

-13.92x

2026-03-31

-16.54x

2025-12-31

-20.40x

2025-09-30

-18.16x

2025-06-30

-19.98x

2025-03-31

-21.13x

2024-12-31

-7.90x

2024-09-30

-1.19x

2024-06-30

-3.84x

2024-03-31

-6.10x

2023-12-31

-6.49x

2023-09-30

-3.12x

2023-06-30

-3.47x

2023-03-31

-6.98x

2022-12-31

-5.49x

2022-09-30

-10.67x

2022-06-30

-6.69x

2022-03-31

-9.02x

2021-12-31

-6.83x

2021-09-30

-5.68x

2021-06-30

-4.20x

2021-03-31

-29.63x

2020-12-31

2.90x

2020-09-30

5.96x

2020-06-30

12.08x

2020-03-31

9.22x

2019-12-31

10.05x

2019-09-30

11.60x

2019-06-30

6.20x

2019-03-31

-3.94x

2018-12-31

-24.86x

2018-09-30

-23.49x

2018-06-30

-18.58x

2018-03-31

-17.46x

2017-12-31

-19.36x

2017-09-30

-23.67x

2017-06-30

-23.76x

2017-03-31

-30.48x

2016-12-31

-31.01x

2016-09-30

34.97x

2016-06-30

-26.65x

2016-03-31

-76.88x

2015-09-30

-2158.09x

2014-09-30

-6423.00x

2014-06-30

-15.49x

2014-03-31

-5.02x

2013-12-31

-3.18x

2013-09-30

-3.41x

Interest Coverage Ratio: -19.95x

CHRS Interest Coverage Ratio

CHRS Average Interest Coverage Ratio Chart

CHRS Current vs Average Interest Coverage Ratio Chart

CHRS Interest Coverage Ratio Metrics

CHRS Competitors' Interest Coverage Ratio

Financial Health Indicators

Interest Coverage Ratio Formula & Definition

Interest Coverage Ratio FAQ

CHRS Interest Coverage Ratio History

Related Metrics